• / Free eNewsletters & Magazine
  • / My Account
Home>Authors>Damien Conover

Damien Conover

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  5. Research
  1. J&J Faces Headwinds in 2015

    The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover .

  2. From Fear of an Overheating U.S. Economy to Doom and Gloom in One Easy Week

    As the eyes of the world turn to the ECB, some are beginning to worry about the strength of the U.S. economy.

  3. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

  4. Prescribe to Pharma for Emerging-Markets Growth

    Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover .

  5. J&J's Strong 2Q Led by Pharmaceuticals

    Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover .

  6. Johnson & Johnson's Pharma Group Leading the Way

    The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover .

  7. Pfizer-Astra Deal Will Get Done

    Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover .

  8. Friday Five: China's Tricky Gambit for Growth

    Plus, more muddling for Europe, a pricey purchase for Merck, and U.S. retail registers ring.

  9. A Shift in Health-Care M&A Activity

    Recent deals have been driven more by tax strategies than therapeutic synergies.

  10. Health Care a Leader in Moat Stocks

    The health-care sector has a higher volume of moat firms compared with other industries, and companies' patent and brand power deliver very strong returns on capital.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.